KR20200022771A - An anti-drunkenness and hangover-alleviating composition and its preparation method - Google Patents
An anti-drunkenness and hangover-alleviating composition and its preparation method Download PDFInfo
- Publication number
- KR20200022771A KR20200022771A KR1020180098822A KR20180098822A KR20200022771A KR 20200022771 A KR20200022771 A KR 20200022771A KR 1020180098822 A KR1020180098822 A KR 1020180098822A KR 20180098822 A KR20180098822 A KR 20180098822A KR 20200022771 A KR20200022771 A KR 20200022771A
- Authority
- KR
- South Korea
- Prior art keywords
- total
- extract
- hangover
- flavanone
- total flavanone
- Prior art date
Links
- 206010019133 Hangover Diseases 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 63
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 claims abstract description 58
- 235000011981 flavanones Nutrition 0.000 claims abstract description 58
- 229930003949 flavanone Natural products 0.000 claims abstract description 57
- 241000218176 Corydalis Species 0.000 claims abstract description 15
- 239000002075 main ingredient Substances 0.000 claims abstract description 4
- 241001289529 Fallopia multiflora Species 0.000 claims abstract description 3
- 150000002207 flavanone derivatives Chemical class 0.000 claims abstract 22
- 229930195210 Ophiopogon Natural products 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 239000002775 capsule Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 239000001116 FEMA 4028 Substances 0.000 claims description 10
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 10
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 10
- 229960004853 betadex Drugs 0.000 claims description 10
- 210000003462 vein Anatomy 0.000 claims description 9
- 239000005913 Maltodextrin Substances 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 8
- 229940035034 maltodextrin Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 6
- 239000003205 fragrance Substances 0.000 claims description 6
- 229940013618 stevioside Drugs 0.000 claims description 6
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019202 steviosides Nutrition 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000001953 recrystallisation Methods 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 244000000231 Sesamum indicum Species 0.000 claims description 3
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 244000248557 Ophiopogon japonicus Species 0.000 claims description 2
- 241000237509 Patinopecten sp. Species 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 235000020637 scallop Nutrition 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 244000184734 Pyrus japonica Species 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 238000005498 polishing Methods 0.000 claims 1
- 235000002020 sage Nutrition 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 241001262617 Japonica Species 0.000 abstract 1
- 241001448424 Ophiopogon Species 0.000 abstract 1
- 150000002208 flavanones Chemical class 0.000 description 35
- 230000035622 drinking Effects 0.000 description 23
- 235000019441 ethanol Nutrition 0.000 description 19
- 208000002173 dizziness Diseases 0.000 description 15
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 6
- 229930003944 flavone Natural products 0.000 description 6
- 150000002212 flavone derivatives Chemical class 0.000 description 6
- 235000011949 flavones Nutrition 0.000 description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000013405 beer Nutrition 0.000 description 4
- 230000035987 intoxication Effects 0.000 description 4
- 231100000566 intoxication Toxicity 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 235000020097 white wine Nutrition 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010001605 Alcohol poisoning Diseases 0.000 description 2
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 2
- 208000029650 alcohol withdrawal Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 244000230712 Narcissus tazetta Species 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/24—Non-sugar sweeteners
- A23V2250/262—Stevioside
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5112—Cyclodextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5114—Dextrins, maltodextrins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Pediatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 의약 분야에 관한 것으로서, 특히 항-주취 및 숙취-완화 기능을 갖는 조성물 및 그 제조 방법에 관한 것이다.TECHNICAL FIELD The present invention relates to the field of medicine, and more particularly, to a composition having an anti-drinking and hangover-relaxing function and a method for producing the same.
보통 음주는 사람들의 신체 건강에 도움이 된다. 그러나, 과도한 음주는 주취(drunkenness) 및 현기증, 두통, 숙취, 및 음주 후 나쁜 품행을 초래하고, 정상 업무 및 대인 관계에 영향을 줄 수 있다. 더 심각한 것은 과도한 음주가 신체 조직과 장기를 손상시킬 수 있다는 것이다. 예를 들면, 연속적인 과도한 음주는 간 세포를 손상시키고 간의 정상적인 신진 대사를 방해할 수 있고, 알코올성 간염 및 간경변을 더욱 초래할 수 있다. 또한, 잦은 음주는 알코올 의존을 초래할 수 고, 이는 말하자면, 알코올 금단 증후군으로 불리는, 갑자기 음주를 중단하거나 또는 알코올 섭취를 줄인 후의 다양한 불편한 신체 증상이 나타날 것이다.Drinking alcohol usually helps people's physical health. However, excessive drinking can lead to drunkiness and dizziness, headaches, hangovers, and bad behavior after drinking and can affect normal work and interpersonal relationships. More seriously, excessive drinking can damage body tissues and organs. For example, continuous excessive drinking can damage liver cells, interfere with normal metabolism of the liver, and further lead to alcoholic hepatitis and cirrhosis. In addition, frequent drinking may result in alcohol dependence, which, as it were, will lead to various uncomfortable physical symptoms, such as alcohol withdrawal syndrome, after suddenly stopping drinking or reducing alcohol consumption.
따라서, 사람들은 음주로 인한 불편함을 완화하기 위해 다양한 방법을 채택하고 있고, 시장에 판매중인 많은 대응 제품도 있다; 그러나 대부분의 제품은 부정확한 치료 효과가 있다.Thus, people are adopting various methods to alleviate the discomfort associated with drinking, and there are many corresponding products on the market; However, most products have inaccurate therapeutic effects.
상기 문제점을 해결하기 위해, 본 발명은 다수의 실험에 기초한 새로운 항-주취 및 숙취-완화 조성물을 제안한다. 상기 조성물은 음주자의 주취 임계값(drunkenness threshold value)을 유의적으로 향상시키고, 주취 및 주취로 인하여 초래된 현기증, 통제 불능 행동 등의 신체 불편함을 방지하고, 대상자의 알코올 금단 증후군을 완화시킬 수 있다. 또한, 상기 조성물은 알코올의 분해를 촉진하고 간세포에서 알코올의 손상을 완화시킬 수 있는 간 보호 성분을 포함하고, 이상적인 항-주취 및 숙취-완화 제품이다.In order to solve the above problem, the present invention proposes a new anti-fragrance and hangover-releasing composition based on a number of experiments. The composition can significantly improve the alcoholic beverage threshold (drunkenness threshold value), prevent bodily discomfort such as dizziness, uncontrollable behavior caused by alcohol and alcohol, and relieve alcohol withdrawal syndrome of the subject have. In addition, the compositions include liver protective ingredients that can promote the breakdown of alcohol and mitigate the damage of alcohol in hepatocytes, and are ideal anti-drink and hangover-relieving products.
상기 기술적 목적을 달성하기 위해, 본 발명은 다음 기술적 방안을 채택한다:In order to achieve the above technical object, the present invention adopts the following technical solution:
적하수오 (Polygonum multiflorum) 총 플라바논 추출물 (total flavanone extract), 현호색 (Rhizoma corydalis) 총 플라바논 추출물 및 소엽맥문동 (Ophiopogon japonicus) 총 플라바논 추출물로부터 선택된 하나 이상을 함유하는 주요 성분을 포함하는, 항-주취 및 숙취-완화 조성물.Anti-gonist, comprising a major component comprising one or more selected from Polygonum multiflorum total flavanone extract, Rhizoma corydalis total flavanone extract, and Ophiopogon japonicus total flavanone extract Alcohol and Hangover-Relieving Compositions.
바람직하게는, 중량부 당, 적하수오 총 플라바논 추출물 0-40, 현호색 총 플라바논 추출물 0-40 및 소엽맥문동 총 플라바논 추출물 20-100을 포함하는, 주요 성분.Preferably, per part by weight, comprising a total amount of Daffodil total flavanone extract 0-40, corydalis total flavanone extract 0-40 and leaflet vegetation total flavanone extract 20-100.
바람직하게는, 상기 적하수오 총 플라바논 추출물 내 총 플라바논 함량은 >50%, 현호색 총 플라바논 추출물 내 총 플라바논 함량은 >80%, 및 소엽맥문동 총 플라바논 추출물 내 총 플라바논 함량은 >80% 이다.Preferably, the total flavanone content in the dropwise total flavanone extract is> 50%, the total flavanone content in corydalis total flavanone extract is> 80%, and the total flavanone content in the leaflet vegetation total flavanone extract is> 80%.
상기 적하수오 총 플라바논 추출물, 현호색 총 플라바논 추출물 및 소엽맥문동 총 플라바논 추출물은 다음 방법에 의해 제조된다:The Total Drainage Total Flavanone Extract, Corydalis Radix Total Flavanone Extract and Leaflet Vegetation Total Flavanone Extract are prepared by the following method:
상기 적하수오, 현호색 및 소엽맥문동을 분쇄함; 물 또는 70% 미만 농도의 에탄올로 상기 분쇄된 산물을 각각 추출함; 상기 추출된 용액을 회수함; 원심분리함; 추출, 매크로포러스 수지 칼럼 크로마토그래피 또는 재결정화를 수행함; 40-50 ℃에서 진공 건조함; 및 각 추출물의 함량이 요구 사항을 충족하는지 확인하는 검출함.Pulverizing the drip, scallop and leaflet veins; Extracting each of the milled products with water or ethanol at a concentration of less than 70%; Recovering the extracted solution; Centrifuge; Performing extraction, macroporous resin column chromatography or recrystallization; Vacuum dried at 40-50 ° C .; And detecting that the content of each extract meets the requirements.
본 발명의 항-주취 및 숙취-완화 조성물은 β-사이클로덱스트린, 말토덱스트린 및 스테비오시드로부터 선택된 하나 이상을 함유하는 보조 성분을 더욱 포함한다.The anti-fragrance and hangover-releasing composition of the present invention further comprises an auxiliary component containing at least one selected from β-cyclodextrin, maltodextrin and stevioside.
바람직하게는, 상기 주요 성분 및 보조 성분의 중량비는 1:(0-3) 이다.Preferably, the weight ratio of the main and auxiliary components is 1: (0-3).
본 발명은 또한, 다음 단계를 포함하는, 항-주취 및 숙취-완화 조성물을 제조하는 방법을 개시한다:The present invention also discloses a method of preparing an anti-drunken and hangover-relaxing composition comprising the following steps:
(1) 적하수오, 현호색 및 소엽맥문동을 분쇄함; 물 또는 70% 미만 농도의 에탄올로 상기 분쇄된 산물을 각각 추출함; 상기 추출된 용액을 회수함; 원심분리함; 추출, , 침전, 매크로포러스 수지 크로마토그래피 또는 재결화를 수행함; 40-50 ℃에서 진공 건조함; 각 추출물의 함량이 요구 사항을 충족하는지 확인하는 검출하여, 상기 적하수오 총 플라바논 추출물, 현호색 총 플라바논 추출물 및 소엽맥문동 총 플라바논 추출물을 수득함; 및 각 추출물을 분쇄하고, 60-메쉬 체로 거름; (1) crushed drip, sesame and leaflet veins; Extracting each of the milled products with water or ethanol at a concentration of less than 70%; Recovering the extracted solution; Centrifuge; Performing extraction, precipitation, macroporous resin chromatography or recrystallization; Vacuum dried at 40-50 ° C .; Detecting that the content of each extract satisfies the requirements, to obtain the above-mentioned drop total gland flavanone extract, corydalis gland total flavanone extract and leaflet vegetation total flavanone extract; And milling each extract and sieving with a 60-mesh sieve;
(2) 중량부 당, 상기 적하수오 총 플라바논 추출물 0-40, 소엽맥문동 총 플라바논 추출물 0-40, 및 소엽맥문동 총 플라바논 추출물 20-100 칭량하고, 그들을 균일하게 혼합하여 주요 성분을 수득함;(2) Per 1 part by weight, weighing 20 to 100 parts of the total dropwise total flavanone extract, 0-40 of the leaflet vegetation extract, and 20-100 of the leaflet vegetation extract, and mixing them uniformly to obtain the main components. box;
(3) 중량부 당, β-사이클로덱스트린 0-100 및 말토덱스트린 0-100, 칭량하고, 그들을 주요 성분과 균일하게 혼합하고, 총 중량 대비 10-50% 물 추가하고 반복적으로 연마, 진공 건조, 분쇄, 및 60-메쉬 체로 거름; 및(3) per part by weight, β-cyclodextrin 0-100 and maltodextrin 0-100, weighed, mixed them uniformly with the main ingredients, added 10-50% water to the total weight and repeatedly polished, vacuum dried, Grinding, and manure with a 60-mesh sieve; And
(4) 0-20 중량부의 스테비오시드 추가, 균일하게 혼합, 멸균, 펠렛화, 및 캡슐, 타블렛 또는 연질약으로 제조함.(4) 0-20 parts by weight of stevioside added, uniformly mixed, sterilized, pelletized, and prepared into capsules, tablets or soft medicines.
본 발명에서 기술된 항-주취 및 숙취-완화 조성물은 소엽맥문동을 포함하고, 보조 성분으로 적하수오 및 소엽맥문동을 주요 구성으로 포함한다. 지원자들에 대한 효과에 대한 관찰에 기초하여, 상기 항-주취 및 숙취-완화 조성물은 주취 임계값을 개선하고, 주취 증상을 완화시키거나 감소시키는 효과가 있음이 입증되었다.The anti-fragrance and hangover-relaxing compositions described in the present invention comprise the leaflet vein sinus and the main component of the dropping sesame and leaflet vein sinus as main components. Based on observations on the effect on volunteers, the anti-drunken and hang-over compositions have been demonstrated to have an effect of improving the alcohol threshold and alleviating or reducing the symptoms of alcohol.
이하, 구체적인 실시예와 조합하여 본 발명을 더욱 설명하지만, 본 발명은 이들 실시예에 제한되지 않는다.Hereinafter, the present invention is further described in combination with specific examples, but the present invention is not limited to these examples.
실시예 1Example 1
적하수오 총 플라바논 추출물, 현호색 총 플라바논 추출물 및 소엽맥문동 총 플라바논 추출물의 제조Preparation of Dripping Sewage Total Flavanone Extract, Corydalis Total Flavanone Extract, and Lobules Leaflet Total Flavanone Extract
목적하는 적하수오 총 플라바논 추출물은 적하수오를 분쇄함; 상기 분쇄된 적하수오를 60% 에탄올로 가열 환류 추출함; 상기 추출된 용액을 회수함; 원심분리함; 상기 상청액을 수집함; 매크로포러스 수지 크로마토그래피를 수행하여 총 플라본 농축 부분을 수득함; 용매를 회수함; 농축함; 40-50 ℃에서 진공 건조함; 및 총 플라본 함량이 >50% 임을 확인하는 검출함에 의해 제조된다. Desired dripping total flavanone extracts pulverized dripping; Heating and refluxing the ground dropwise water with 60% ethanol; Recovering the extracted solution; Centrifuge; Collecting the supernatant; Performing macroporous resin chromatography to obtain a total flavone enriched portion; Recovering the solvent; Concentrated; Vacuum dried at 40-50 ° C .; And detecting to confirm that the total flavone content is> 50%.
목적하는 현호색 총 플라바논 추출물은 현호색을 분쇄함; 상기 분쇄된 현호색을 40% 에탄올로 초음파 추출함; 상기 추출된 용액을 회수함; 원심분리함; 상기 상청액을 수집함; 에틸 아세테이트로 추출 수행하여 총 플라본 농축 부분을 수득함; 용매를 회수함; 농축함; 40-50 ℃에서 진공 건조함; 및 총 플라본 함량이 >80% 임을 확인하는 검출함에 의해 제조된다.Desired corydalis total flavanone extracts pulverize corydalis; Ultrasonically extracting the ground corydale with 40% ethanol; Recovering the extracted solution; Centrifuge; Collecting the supernatant; Extraction with ethyl acetate to give the total flavone concentrate portion; Recovering the solvent; Concentrated; Vacuum dried at 40-50 ° C .; And detecting to confirm that the total flavone content is> 80%.
목적하는 소엽맥문동 총 플라바논 추출물은 소엽맥문동을 분쇄함; 상기 분쇄된 소엽맥문동을 60% 에탄올로 가열 환류 추출함; 상기 추출된 용액을 회수함; 원심분리함; 상기 상청액을 수집함; 재결정화를 수행하여 플라본 농축 부분을 수득함; 40-50 ℃에서 진공 건조함; 및 총 플라본 함량이 >80% 임을 확인하는 검출함에 의해 제조된다. Desired leaflet vein pulmonary total flavanone extract pulverize leaflet vein sinus; Extracting the pulverized leafy veins from the heated reflux with 60% ethanol; Recovering the extracted solution; Centrifuge; Collecting the supernatant; Recrystallization is performed to obtain a flavone concentrate portion; Vacuum dried at 40-50 ° C .; And detecting to confirm that the total flavone content is> 80%.
실시예 2Example 2
항-주취 및 숙취-완화 캡슐은, 적하수오 총 플라바논 추출물, 현호색 총 플라바논 추출물 및 소엽맥문동 총 플라바논 추출물을 주요 성분으로 포함하고, 및 β-사이클로덱스트린을 보조 성분으로 포함하고 및 다음 단계를 통해 제조된다:The anti-drunken and hangover-relieving capsules contain a total of flavonoid extract, corydale total flavanone extract, and leaflet vegetation total flavanone extract as main components, and β-cyclodextrin as a secondary component and the next step. Is manufactured through:
(1) 실시예 1에서 제조된 500g의 칡(Puerariae lobatae) 총 플라바논 추출물, 500g의 현호색 총 플라바논 추출물 및 5000g의 소엽맥문동 총 플라바논 추출물을 칭량, 분쇄, 60-메쉬 체로 거름; 및 4000g의 β-사이클로덱스트린을 칭량하고, 상기 물질들을 균일하게 혼합함. (1) 500 g of Puerariae lobatae total flavanone extract prepared in Example 1, 500 g of corydalis total flavanone extract and 5000 g of lobular vegetation total flavanone extract were weighed, pulverized and filtered through a 60-mesh sieve; And 4000 g of β-cyclodextrin and mixing the materials uniformly.
(2) 3000ml의 물을 추가, 반복적으로 연마, 물 함량이 <5% 될때까지 40-50 ℃에서 진공 건조, 분쇄, 및 60-메쉬 체로 거름;(2) 3000 ml of water was added, repeatedly polished, vacuum dried at 40-50 ° C. until the water content was <5%, pulverized, and sieved through a 60-mesh sieve;
(3) 멸균 수행 후, 20-40% 습도 환경 하에서 펠렛화하여, 20-40 메쉬의 입자를 수득함; 및 (3) after sterilization, pelleted under 20-40% humidity environment to obtain 20-40 mesh of particles; And
(4) 50% 이하의 습도 환경 하에서 상기 입자를 캡슐 내로 충진하여, 각 중량 0.5g을 갖는, 캡슐을 수득함.(4) Filling the particles into capsules under a humidity environment of 50% or less, to obtain capsules having a weight of 0.5 g each.
투여 방법 및 투여량 : 경구 투여, 매회 두 캡슐, 음주 30 분 전에 따뜻한 물과 함께 투여.Method of administration and dosage: Oral administration, two capsules each time, with warm water 30 minutes before drinking.
실시예 3Example 3
항-주취 및 숙취-완화 연질약은, 소엽맥문동 총 플라바논 추출물을 주요 성분으로 포함하고, β-사이클로덱스트린, 말토덱스트린 및 스테비오시드를 보조 성분으로 포함하고; 및 다음 단계를 통해 제조된다:Anti-drinking and hangover-softening drugs include leaflet vegetation total flavanone extract as a main component and β-cyclodextrin, maltodextrin and stevioside as auxiliary components; And by the following steps:
(1) 실시예 1에서 제조된 5000g의 소엽맥문동 총 플라바논 추출물을 칭량하고, 5000g의 β-사이클로덱스트린 및 5000g의 말토덱스트린을 칭량하고, 상기 물질들을 균일하게 혼합함. (1) Weigh 5000 g of the leaflet vegetation total flavanone extract prepared in Example 1, weigh 5000 g of β-cyclodextrin and 5000 g maltodextrin, and mix the materials uniformly.
(2) 5000ml의 물을 추가, 반복적으로 연마, 물 함량이 <5% 될 때까지 40-50 ℃에서 진공 건조, 분쇄, 및 60- 메쉬 체로 거름;(2) 5000 ml of water is added, repeatedly polished, vacuum dried at 40-50 ° C. until the water content is <5%, pulverized, and filtered with a 60-mesh sieve;
(3) 1000g의 스테비오시드를 추가, 균일하게 혼합, 멸균 수행 후, 20-40% 습도 환경 하에서 펠렛화하여, 20-40 메쉬의 입자를 수득함; 및 (3) 1000 g of stevioside was added, mixed uniformly, and sterilized before being pelletized in a 20-40% humidity environment to obtain 20-40 mesh of particles; And
(4) 50% 이하의 습도 환경 하에서 상기 입자를 백(bag) 내로 충진하여, 각 중량 2g 을 갖는, 열질약을 수득함.(4) Filling the particles into a bag under a humidity environment of 50% or less, to obtain a thermotropic drug having a weight of 2 g each.
투여 방법 및 투여량 : 경구 투여, 매회 두 백, 음주 30 분 전 또는 음주 후에 (연질약이 끓인 물에 의해 용해된 이후에) 투여.Method of administration and dosage: Oral administration, two bags each time, 30 minutes before drinking or after drinking (after the soft medicine is dissolved in boiled water).
실시예 4Example 4
항-주취 및 숙취-완화 타블렛은, 현호색 총 플라바논 추출물 및 소엽맥문동 총 플라바논 추출물을 주요 성분으로 포함하고, 및 β-사이클로덱스트린 및 말토덱스트린을 보조 성분으로 포함하고; 및 다음 단계를 통해 제조된다:Anti-drunken and hangover-relieving tablets comprise corydalis total flavanone extract and leaflet vegetation total flavanone extract as main components, and β-cyclodextrin and maltodextrin as auxiliary components; And by the following steps:
(1) 실시예 1에서 제조된 300g의 현호색 총 플라바논 추출물 및 2500g의 소엽맥문동 총 플라바논 추출을 칭량함; 및 2500g의 β-사이클로덱스트린 및2500g의 말토덱스트린을 칭량하고, 및 상기 물질들을 균일하게 혼합함. (1) Weigh 300 g of Corydalis gland total flavanon extract and 2500 g of leaflet vegetation total flavanone extract prepared in Example 1; And 2500 g of β-cyclodextrin and 2500 g maltodextrin, and mixing the materials uniformly.
(2) 멸균 수행 후, 20-40% 습도 환경 하에서 펠렛화하여, 20-40 메쉬의 입자를 수득함; 및 타정하여 각 중량 0.3g 을 갖는 타블렛을 수득함. (2) after sterilization, pelleted under 20-40% humidity environment to obtain 20-40 mesh of particles; And tableting to give tablets having a weight of 0.3 g each.
투여 방법 및 투여량 : 경구 투여, 매회 2-3 타블렛, 음주 30 분 전 또는 음주 후에 투여.Method of administration and dosage: Oral administration, 2-3 tablets each time, 30 minutes before or after drinking.
실험 실시예 1Experimental Example 1
실시예 2에서 제조된 항-주취 숙취-완화 캡슐의 효과 관찰Observation of the Effect of the Anti-Drunk Hangover-Relieving Capsules Prepared in Example 2
캡슐은 30 명의 지원자에 의해 실험되었다. 그들은 음주 30 분 전에 두 캡슐씩 투여받았고, 음주 후 현기증과 주취 증상이 관찰되었다. 30 명의 지원자 모두가 다음의 피드백을 주었다: 캡슐이 효과적이었고, 음주자의 주취를 초래하는 알코올의 양을 유의적으로 증가시키고, 주취 및 주취에 의해 초래되는 현기증 및 행동 제어 상실과 같은 신체 불편함을 예방할 수 있다. 전형적인 실시예는 다음과 같다:Capsules were tested by 30 volunteers. They were given two capsules 30 minutes before drinking and dizziness and intoxication were observed after drinking. All 30 volunteers gave the following feedback: The capsules were effective, significantly increased the amount of alcohol causing alcohol intoxication, and increased physical discomfort such as dizziness and loss of behavioral control caused by alcohol and intoxication. It can be prevented. Typical examples are as follows:
매우 소량의 맥주를 마신 후 보통 현기증을 앓는 (셴 (Shen)이라는 성을 가진) 40 세의 남성 지원자는, 음주 30 분 전에 캡슐 두 개를 투여받았고, 100g의 52% 백포도주를 마신 후 현기증을 느끼지 않았다.A 40-year-old male volunteer (who has a last name, Shen) who drank a very small amount of beer, received two capsules 30 minutes before drinking and felt dizzy after drinking 100g of 52% white wine Did.
네 병의 맥주를 마신 후 보통 현미경을 앓는 (푸 (Fu)라는 성을 가진) 22 세의 남성 지원자는, 음주 30 분 전에 캡슐 두 개를 투여받았고, 일곱 병의 맥주를 마신 후 현기증을 느끼지 않았다.A 22-year-old male volunteer (with a surname named Fu) who usually suffered from a microscope after drinking four bottles of beer, received two capsules 30 minutes before drinking, and did not feel dizzy after drinking seven bottles of beer .
실험 실시예 2Experimental Example 2
실시예 3에서 제조된 항-주취 숙취-완화 연질약의 효과 관찰Observation of the effects of the anti-drunken hangover-softening agent prepared in Example 3
연질약은 5 명의 지원자에 의해 실험되었다. 그들은 음주에 의해 초래되는 현기증을 느낀 후 두 백의 연질약을 투여받았고, 현기증 증상에 대한 완화 효과가 관찰되었다. 5 명의 지원자 모두가 다음의 피드백을 주었다: 상기 연질약은 효과적이었고, 현기증 증상을 완화하고 주취 시간을 단축시킬 수 있었다.Soft pills were tested by five volunteers. After receiving dizziness caused by drinking, they received two hundred soft pills, and a mitigating effect on dizziness symptoms was observed. All five volunteers gave the following feedback: The soft medication was effective and could alleviate the dizziness symptoms and shorten the infusion time.
실험 실시예 3Experimental Example 3
실시예 4에서 제조된 항-주취 숙취-완화 타블렛의 효과 관찰Observing the Effect of the Anti-Drunk Hangover-Relieving Tablet Prepared in Example 4
캡슐은 16 명의 지원자에 의해 실험되었다. 그들은 음주 30 분 전에 두 캡슐씩 투여받았고, 음주 후 현기증 및 주취 증상이 관찰되었다. 그들 중, 15 명의 지원자가 다음의 피드백을 주었다: 타블렛이 효과적이었고, 음주자의 주취를 초래하는 알코올의 양을 유의적으로 증가시키고, 주취 및 주취에 의해 초래되는 현기증 및 행동 제어 상실과 같은 신체 불편함을 예방할 수 있다. 전형적인 실시예는 다음과 같다:Capsules were tested by 16 volunteers. They were given two capsules 30 minutes before drinking and dizziness and intoxication were observed after drinking. Of them, 15 volunteers gave the following feedback: The tablet was effective, significantly increased the amount of alcohol causing alcohol intoxication, and physical discomfort such as dizziness and loss of behavioral control caused by alcohol and intoxication Can be prevented. Typical examples are as follows:
보통 많은 알코올을 마시고 이내 현기증을 앓는 (가오 (Gao)라는 성을 가진) 31 세의 남성 지원자는, 음주 30 분 전에 타블렛 두 개를 투여받았고, 100g의 52% 백포도주를 마신 후 현기증을 느끼지 않았다.A 31-year-old male volunteer (usually named Gao) who drank a lot of alcohol and soon became dizzy, did not feel dizzy after drinking two tablets 30 minutes before drinking and 52% white wine.
보통 최대 한 병의 맥주를 마신 후 현기증을 앓고 백포도주를 마시지 않는 (장 (Zhang)이라는 성을 가진) 36 세의 남성 지원자는, 음주 30 분 전에 타블렛 두 개를 투여받았고, 100g의 52% 백포도주를 마신 후 현기증을 느끼지 않았다.A 36-year-old male volunteer (who has a surname called Zhang) who is dizzy and doesn't drink white wine after drinking up to one bottle of beer, received two tablets 30 minutes before drinking, and received 100g of 52% white wine. Did not feel dizzy after drinking.
Claims (7)
상기 적하수오, 현호색 및 소엽맥문동을 분쇄함; 물 또는 70% 미만 농도의 에탄올로 상기 분쇄된 산물을 각각 추출함; 상기 추출된 용액을 회수함; 원심분리함; 추출, 매크로포러스 수지 칼럼 크로마토그래피 또는 재결정화를 수행함; 40-50 ℃에서 진공 건조함; 및 각 추출물의 함량이 요구 사항을 충족하는지 확인하는 검출함.The anti-drinking and hangover-relaxing composition according to claim 3, wherein the total dropwise total flavanone extract, corydale total flavanone extract and leaflet vegetation total flavanone extract are prepared by the following method:
Pulverizing the drip, scallop and leaflet veins; Extracting each of the milled products with water or ethanol at a concentration of less than 70%; Recovering the extracted solution; Centrifuge; Performing extraction, macroporous resin column chromatography or recrystallization; Vacuum dried at 40-50 ° C .; And detecting that the content of each extract meets the requirements.
(1) 적하수오, 현호색 및 소엽맥문동을 분쇄함; 물 또는 70% 미만 농도의 에탄올로 상기 분쇄된 산물을 각각 추출함; 상기 추출된 용액을 회수함; 원심분리함; 추출, 매크로포러스 수지 칼럼 크로마토그래피 또는 재결정화를 수행함; 40-50 ℃에서 진공 건조함; 각 추출물의 함량이 요구 사항을 충족하는지 확인하는 검출하여, 상기 적하수오 총 플라바논 추출물, 현호색 총 플라바논 추출물 및 소엽맥문동 총 플라바논 추출물을 수득함; 및 각 추출물을 분쇄하고, 60-메쉬 체로 거름;
(2) 중량부 당, 상기 적하수오 총 플라바논 추출물 0-40, 소엽맥문동 총 플라바논 추출물 0-40, 및 소엽맥문동 총 플라바논 추출물 20-100 칭량하고, 그들을 균일하게 혼합하여 주요 성분을 수득함;
(3) 중량부 당, β-사이클로덱스트린 0-100 및 말토덱스트린 0-100 칭량하고, 그들을 주요 성분과 균일하게 혼합하고, 총 중량 대비 10-50% 물 추가하고 반복적으로 연마, 진공 건조, 분쇄, 및 60-메쉬 체로 거름; 및
(4) 0-20 중량부의 스테비오시드 추가, 균일하게 혼합, 멸균, 펠렛화, 및 캡슐, 타블렛 또는 연질약으로 제조함.A method for preparing an anti-drink and hangover-releasing composition comprising the following steps:
(1) crushed drip, sesame and leaflet veins; Extracting each of the milled products with water or ethanol at a concentration of less than 70%; Recovering the extracted solution; Centrifuge; Performing extraction, macroporous resin column chromatography or recrystallization; Vacuum dried at 40-50 ° C .; Detecting that the content of each extract satisfies the requirements, to obtain the above-mentioned dulciflora total flavanone extract, corydalis total flavanone extract and leaflet vegetation total flavanone extract; And milling each extract and sieving with a 60-mesh sieve;
(2) per weight part, weighing 20 to 100 drops of the total dropwise total flavanone extract, 0-40 of the leaflet vegetation extract, and 20-100 of the leaflet vegetation extract, and mixing them uniformly to obtain the main components. box;
(3) per part by weight, β-cyclodextrin 0-100 and maltodextrin 0-100 are weighed, mix them uniformly with the main ingredients, add 10-50% water to the total weight and repeat polishing, vacuum drying, grinding , And 60-mesh sieve; And
(4) 0-20 parts by weight of stevioside added, uniformly mixed, sterilized, pelletized, and prepared into capsules, tablets or soft medicines.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180098822A KR20200022771A (en) | 2018-08-23 | 2018-08-23 | An anti-drunkenness and hangover-alleviating composition and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180098822A KR20200022771A (en) | 2018-08-23 | 2018-08-23 | An anti-drunkenness and hangover-alleviating composition and its preparation method |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20200022771A true KR20200022771A (en) | 2020-03-04 |
Family
ID=69783316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180098822A KR20200022771A (en) | 2018-08-23 | 2018-08-23 | An anti-drunkenness and hangover-alleviating composition and its preparation method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20200022771A (en) |
-
2018
- 2018-08-23 KR KR1020180098822A patent/KR20200022771A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4413995B2 (en) | Medicinal plant extract with anti-obesity effect | |
KR102615399B1 (en) | A composition for the prevention or treatment of hepatitis C virus infection disease comprising a compound isolated from Agrimonia pilosa extract and Galla rhois extract | |
CN111803608A (en) | A Chinese medicinal composition with antiviral effect | |
CN111011681A (en) | Emblic leafflower fruit extract for dispelling effects of alcohol and protecting liver and preparation method and application thereof | |
CN102860552A (en) | Process for preparing lotus leaf weight-reducing beverage | |
CN104815138A (en) | Immature bitter orange extract, preparation and application | |
KR20200136207A (en) | Composition for anti-allergy comprising extract of lithospermum erythrorhizon | |
KR20200009824A (en) | An anti-drunkenness and hangover-alleviating composition and its preparation method | |
KR100824970B1 (en) | Polygoni cuspidati radix extract for allergic disease and process for preparation thereof | |
KR20200022771A (en) | An anti-drunkenness and hangover-alleviating composition and its preparation method | |
KR101537856B1 (en) | A pharmaceutical composition for preventing and treating nonalcoholic fatty liver disease comprising extraction fraction with enhanced gincenoside rb1 from panax ginseng as an active ingredient | |
CN103830374A (en) | Application of three-leaf glycolipid-removal medicine in hyperuricemia | |
KR20030080296A (en) | Composition containing saponin fraction and derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
KR20180118413A (en) | Composition comprising Cordycepin as an effective ingredient for preventing or treating of Liver cancer and Method for preparing Butanol fraction of Cordyceps militaris | |
KR20200020287A (en) | An anti-drunkenness and hangover-alleviating composition and its preparation method | |
KR20230058792A (en) | An anti-drunkenness and hangover-alleviating composition and its preparation method | |
CN110624006A (en) | A health wine containing effective components of fructus Quzhazhii | |
CN104784371A (en) | Pharmaceutical composition for resisting alcoholic liver injury and preparation method thereof | |
KR100533505B1 (en) | Health supplement food containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
KR20200004196A (en) | An anti-drunkenness and hangover-alleviating composition and its preparation method | |
KR100750873B1 (en) | A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease | |
EP1498131B1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa | |
CN104585469A (en) | Chewing gum having protective effect on alcoholic liver injury and preparation method of chewing gum | |
DE102019203483A1 (en) | AN ANTI-DRUNK AND HANGOVER RELIEF COMPOSITION AND THEIR METHOD OF MANUFACTURING | |
JP2020007250A (en) | Anti-drunkenness and hangover-mitigating composition, and method of preparing the same |